Lantern Pharma Secures European Patent for LP-284, Advancing Global Commercialization Strategy

Lantern Pharma (NASDAQ: LTRN) has reached a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate targeting relapsed or refractory non-Hodgkin’s lymphoma. This patent, expected to provide exclusivity through 2039, complements existing protections in the U.S. and Japan, marking a crucial advancement in the drug's global commercialization strategy.

Developed using Lantern Pharma's RADR(R) AI platform, LP-284 is currently in Phase 1 clinical trials and has received Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL). These designations highlight the drug's potential to meet significant unmet needs in these areas, with a global target market estimated at $4 billion. The efficiency and speed of LP-284's development, facilitated by the RADR(R) platform, enhance its attractiveness for strategic partnerships.

The RADR(R) platform utilizes over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms, enabling Lantern Pharma to significantly reduce the time and cost of bringing new therapies from AI insights to clinical trials. This approach has streamlined the process to an average of 2-3 years and approximately $2.5 million per program, showcasing the platform's capability to revolutionize oncology drug development.

This patent approval not only bolsters Lantern Pharma's intellectual property portfolio but also exemplifies the increasing impact of AI in addressing the complexities of cancer treatment. By leveraging AI, Lantern Pharma is pioneering solutions for patients with limited treatment options, offering new hope in the fight against cancer. For more information on Lantern Pharma's innovative approaches, visit https://www.lanternpharma.com.